Health
Factor Therapeutics tests new weapon in battle of diseases
Columnists
Why superbug tester Genetic Signatures is hoping for a big flu season
Columnists
Antisense is about to start its muscular dystrophy trial
Columnists
Invitrocue is promising cheap, personlised cancer tests
Columnists
Can cancer drug developer Prescient follow in Loxo’s billion-dollar footsteps?
Columnists
What’s next for Innate Immuno after Plan B sends shares up 300pc
Columnists
Why investors shouldn’t be deaf to Nuheara’s appeal
Columnists